Lupin receives warning letter from USFDA for Goa and Indore sites

07 Nov 2017 Evaluate

Lupin has received a warning letter issued by the United States Food and Drug Administration (USFDA) on November 6, 2017, for its formulation manufacturing facilities at Goa and Indore (Pithampur Unit II). While there will be no disruption of existing product supplies from either of these locations, there will likely be a delay of new product approvals from these two facilities.

Earlier, the company had received three Form 483 observations in Goa on April 7, 2017 and six Form 483 observations in Pithampur (Unit II) on May 19, 2017.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2071.35 -26.30 (-1.25%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×